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Abstract 
Objectives: Gingival enlargement as an adverse effects of drugs has been found to be long associated with the use of 
anticonvulsants; phenytoin, anti-hypertensives; calcium channel blockers and immunosuppressants; cyclosporine. 
Nifedepine was found to cause gingival overgrowth with an incidence ranging from 15-85%.  However, Amlodepi-
ne a relatively newer agent of the same group which is being routinely and vastly prescribed either alone or as part 
of combination therapy to middle to older aged adults has also been found to exhibit this adverse effect with very 
few cases reported till date. The effect of the dose of amlodepine on the severity of gingival enlargement needs to 
be assessed. 
Study design: A clinical presentation of a series of five cases in the age range of 45-65 yrs with gingival over-growth 
as a side effect of therapy with amlodepine is presented with prescription of variable doses of 2.5 mg, 5 mg and 10 
mg per day. A brief review on the pathogenesis of this condition, commonly associated etiological mechanisms and 
sequence of periodontal therapy rendered have also been included.
Conclusion: Irrespective of the dose of amlodepine administered, gingival enlargement continues to be a predo-
minant side effect in all of the five cases presented. The accentuated gingival contours accumulate plaque leading 
further to the destruction of the underlying periodontium. Dental professionals need to identify and then guide the 
patient to seek necessary medical intervention.
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Introduction
Gingival enlargements are commonly seen as a side 
effect of various groups of medications which inclu-
des: Anticonvulsants, anti-hypertensives; esp. Calcium 
channel blockers and immunosuppressants. Amlodepi-
ne is a third generation dihydropyridine which has been 
found to be very useful in middle aged to older aged 
adult patients for various cardiovascular conditions. It 
functions by inhibiting calcium ion influx across cell 
membranes of heart and smooth muscles thereby, bloc-
king its intra-cellular mobilization (1). The incidence of 
gingival enlargement with amlodepine was reported to 
be much lesser than nifedepine (2,3), however; recently 
large numbers of cases are being highlighted. Clinically, 
the enlargement is usually seen 3-6 months following 
the initiation of the drug in question. The overgrowth of 
the gums is generally painless and predominantly invol-
ves the maxillary and mandibular anterior teeth usually 
affecting the marginal and inter-dental gingiva (2). When 
uncomplicated by inflammation the lesion appears firm, 
pale pink and resilient with a minutely lobulated surface 
and no tendency to bleed. However, gingival enlarge-
ments as a side effect of drugs are usually superimposed 
with an inflammatory condition due to development of 
unfavorable gingival contours. The enlarged gingival 
tissues accumulate plaque and also hinder the mainte-
nance of routine oral hygiene which poses a major pro-
blem resulting in the destruction of the underlying bone 
and attachment loss leading to periodontitis (4). Very 
few cases of amlodipine induced gingival enlargements 
have been reported till date (5-7), as a result of which it 
continues to be vastly prescribed. This presentation of 
5 cases attempts to bring to light the existence of this 
adverse effect with the use of Amlodepine not as a rarity 
but a routinely observed finding in patients who have 
been prescribed this drug for various cardiac conditions. 
The patients discussed were on different doses of amlo-
dipine either alone or in conjunction with other groups 
of anti-hypertensives. The effect of the dose of amlodi-
pine on the severity of gingival enlargement was also 
assessed.
Case Series
All of the five cases presented to the dental office with 
a similar complaint of generalized swelling in the gums 
with bleeding and suppuration from them. On evaluating 
their medical histories all of them were hypertensives 
and on amlodipine therapy. The first case was of a 45 year 
old lady who gave a positive history of hypertension and 
hypothyroidism and was on medication for the same. On 
exploring further the anti-hypertensive drug identified 
was amlodipine 10mg (Amlopres®) taken daily since last 
one year and Thyroxine 100 microgram (Thyronorm®). 
On clinical examination, a large bulbous enlargement of 
the gums was seen in relation to left lower lateral inci-
sor and canine region. The swelling involved the margi-
nal gingiva, inter-dental papilla as well as the attached 
gingiva and extended into the vestibule. On examining 
the rest of the oral cavity, the marginal and inter-dental 
gingiva of almost all the teeth were enlarged especially 
in the maxillary and mandibular anterior region with a 
superimposed inflammatory component. (Fig. 1)
The second case was that of a 60 year old man who 
presented to the out-patient department with a chief 
complaint of swelling in the gums in relation to the left 
lower back tooth region since 6 months. The swelling 
was painful on mastication and interfered with the pla-
cement of the patient’s removable prosthesis. Medical 
history revealed the patient to be hypertensive and was 
taking amlodipine 5mg as a single daily dose since 2 
yrs. Clinical examination revealed that the marginal and 
inter-dental papillary gingival tissues were enlarged es-
pecially in relation to the upper and lower anterior teeth. 
The tissues appeared firm and fibrotic with a mulberry 
appearance on the surface. Additionally, a large bulbous 
enlarged gingiva around the left lower third molar region 
extending from the mesial aspect adjoining an edentulo-
us space to the buccal and distal aspect of the third molar 
was seen. (Fig. 2)
The remaining three cases were on a combination of 
amlodepine 2.5mg and atenolol 25 mg once daily since 
Fig. 1. Photograph showing clinical presentation of Case No.1
Fig. 2. Photograph showing clinical presentation of Case no. 2 
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2-3 years. The first of these cases was additionally dia-
betic and also gave a history of angina 3 years back. This 
patient had been prescribed various drugs due to the pre-
vailing cardiac condition. The other two cases were only 
hypertensive with no other systemic complicating fac-
tors. Clinical evaluation revealed diffuse gingival over-
growth especially in relation to upper and lower anterior 
teeth, and also involving the marginal and inter-dental 
papilla of the posterior regions. Bleeding on probing and 
suppuration were elicited with presence of copious pla-
que and calculus deposits. (Fig. 3a) The clinical details 
of the cases have been tabulated. (Table 1)
Based on clinical evaluation and radiographic as-
sessment a provisional diagnosis of amlodepine induced 
drug enlargement superimposed with inflammation was 
established. Phase-I periodontal therapy comprising me-
chanical and chemical removal of plaque and calculus as 
well as patient instructions on oral hygiene maintenance 
was initiated. The patient was simultaneously advised to 
seek medical consultation. Following oral prophylaxis 
and substitution of amlodipine, significant improvement 
in the gingival tissues was observed (Fig. 3b). However, 
the OPG X-rays of these patients revealed the presence 
of generalized underlying bone loss. The gingival con-
tours were un-esthetic, difficult to maintain and favored 
plaque accumulation leading to further destruction of the 
attachment apparatus. Hence, phase II periodontal thera-
py was performed with an internal bevel gingivectomy 
and flap operation. The tissues excised were duly sent 
for histo-pathological assessment which revealed the 
presence of parakeratinized epithelium with acanthosis 
and elongated rete-pegs, connective tissue fibrosis with 
inflammatory cells, few scattered giant cells and capi-
llaries indicating a superimposed inflammation. This 
further confirmed our diagnosis of drug associated gin-
Case 
No. Age Sex
Treatment 
time with
Amlodepine
Dose of 
Amlo-
depine
Presence 
of other 
diseases
Other drugs prescribed 
(dose /day) Treatment rendered
1. 45 yrs Female One year 10mg
Hypothyroi-
dism
Thyroxin
100 microgram Plaque control • 
measures
Oral hygiene • 
instructions
Scaling/ root • 
planing
Internal bevel • 
gingivectomy 
with flap surgery
Regular mainte-• 
nance & perio-
dic follow up.
2. 60 yrs Male Two years 5 mg Nil Nil
3. 65 yrs Female Five years 2.5mg
Type II • 
Diabetes 
Mellitus
Angina• 
Atenolol 25mg• 
Metformin 1000 mg• 
Ecosprin 75 mg• 
Atorvastatin• 
4 45 yrs Female Two years 2.5 mg Nil Nil
5. 55 yrs Female Three years 2.5 mg Nil Nil
Table 1. Details of the demographics, medical history and treatment of the clinical cases
gival enlargement. Post-operative evaluations revealed 
that good physiological contours for the patient had been 
achieved favoring good plaque control. 
Discussion
Calcium channel blockers comprise of three chemical 
Figure 3. A. Photograph showing clinical presentation of Case no. 3
B. Photograph showing Case No. 3 two months following 
amlodipine substitution and phase I therapy.
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families viz. dihydropyridines including nifedepine, 
amlodipine, felodipine etc., phenylalkylamines which 
includes verapamil and benzothiazepines which includes 
diltiazem. Compared to conventional therapy (diuretics 
and beta blockers), calcium channel blockers have been 
found to be more effective and hence these are more fre-
quently prescribed (1). The dihydropyridines have been 
found to be associated with enlargement of the gums 
with nifedepine having the highest incidence of about 
6% (3). Amlodipine however is also being found to be 
associated with gingival overgrowth and more and more 
such cases are being reported. A recent study comparing 
the effect of calcium channel blockers vis-à-vis Renin 
angiotensin system drugs showed a twofold greater en-
largement of the gums with the current use of the former 
category of drugs. This association was dose dependant 
and greatest for dihydropyridine derivatives (8). In the 
case series presented, different doses of amlodepine did 
not correlate with the severity of the clinical presenta-
tion. 
The underlying mechanism for the pathogenesis of this 
gingival over-growth remains to be fully understood. 
These drugs which affect intracellular calcium metabo-
lism or transport may in some patients stimulate gingival 
fibroblasts to cause increased deposition of extracellular 
matrix components, such as glycosaminoglycans (2). 
The other proposed non-inflammatory mechanisms in-
clude defective collagenase activity, blockage of aldos-
terone synthesis in adrenal cortex which is also calcium 
dependent and causes a consequent feedback increase in 
ACTH level (9), and up-regulation of the keratinocyte 
growth factor (10). Alterations in the cytokine balances 
may contribute more significantly to the development 
and maintenance of gingival overgrowth. Proliferation 
and differentiation of connective tissue cells and produc-
tion of extracellular matrix are controlled by cytokines 
that initiate signaling cascades mediated by specific re-
ceptors. Recent studies have demonstrated abnormally 
high levels of specific cytokines such as IL-6, IL-1beta, 
platelet derived growth factor (PDGF-B), Fibroblast 
growth factor (FGF-2), Transforming growth factor 
(TGF-beta) and connective tissue growth factor (CTGF) 
in gingival overgrowth tissues (11). 
Drug induced gingival enlargements are usually asso-
ciated with a superimposed inflammatory component 
which has to be minimized as it is a major contributor 
to the gingival overgrowth (12). Scrupulous oral hygie-
ne maintenance by effective plaque control strategies 
both home care and professional need to be taken care 
of. This helps in decreasing the degree of gingival over-
growth present, improves overall gingival health and 
helps maintain attachment levels. In cases with severe 
gingival overgrowth one needs to consider the substitu-
tion of amlodipine with isradipine, lercanidipine and la-
cidipine which are the newer fourth generation dihydro-
pyridines or other classes of anti-hypertensives such as 
beta blockers, A.C.E inhibitors or thiazide derivatives. 
Discontinuing the causative drug has been found to re-
duce the gingival overgrowth (13), however, to assist the 
patient in plaque control as well as from an esthetic point 
of view surgical correction may be deemed necessary. 
Cases in which there is no underlying bone loss, external 
bevel gingivectomy and gingivoplasty is done. In cases 
with presence of attachment loss and underlying osseous 
defects, a procedure called internal bevel gingivectomy 
with flap operation is performed so as to be able to re-
sect the gingival overgrowth and in addition treat the 
underlying osseous defects (12, 14). All of the five cases 
that are presented had some degree of moderate to se-
vere alveolar bone loss and hence internal bevel gingi-
vectomy was the treatment of our choice. The patients 
were followed up for a period of up-to one year and with 
drug substitution and plaque control, no recurrences 
were seen. On clinical assessment, the effect of amlo-
dipine on gingival tissues was probably not dose related 
because even 2.5mg of amlodepine had resulted in a sig-
nificant gingival enlargement. This probably contradicts 
Jorgenson’s study on cardiac patients taking amlodipine 
at a dose of 5mg/day and showing no incidence of gingi-
val overgrowth (15). Importance of plaque control needs 
a special emphasis here as it could be a major contribu-
ting factor for accentuating the enlargement even at low 
serum levels of amlodipine.
Conclusions
One needs to abreast this issue to the various medicine 
experts to bring this fact to light and to minimize the 
prescriptions or practice care while prescribing the inno-
cuous appearing Amlodepine. Even with minimal dose 
of amlodepine a significant gingival enlargement is seen 
hence, regular follow up with suitable dental referral for 
evaluating gingival and periodontal status becomes im-
minent. Dental professionals need to identify and then 
guide the patient to seek necessary medical interven-
tion.
References
Levine CB, Fahrbach KR, Frame D, Connelly JE, Estok RP, Sto-1. 
ne LR et al. Effect of amlodipine on systolic blood pressure. Clin 
Ther. 2003; 25: 35-57.
Dongari-Bagtzoglou A; Research, Science and Therapy Commit-2. 
tee, American Academy of Periodontology. Drug associated gingi-
val enlargement. J Periodontol. 2004; 75: 1424-31.
Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thoma-3. 
son JM. Prevalence of gingival overgrowth induced by calcium 
channel blockers: A community based study. J Periodontol. 1999; 
70: 63-7.
Hassell TM, Hefti AF. Drug induced gingival overgrowth: Old pro-4. 
blem, new problem. Crit Rev Oral Biol Med. 1991; 2:103-37.
Triveni MG, Rudrakshi C, Mehta DS. Amlodipine-induced gingi-5. 
val overgrowth. J Indian Soc Periodontol. 2009; 13: 160-3.
Lafzi A, Farahani RMZ, Shoja MAM. Amlodipine-induced gingi-6. 
val hyperplasia. Med Oral Patol Oral Cir Bucal. 2006; 11:E480-2.
Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR: Amlo-7. 
e394
J Clin Exp Dent. 2011;3(Suppl1):e390-4.                                            Amlodepine induced gingival enlargement.
dipine induced gingival overgrowth. J Clin Periodontol. 1994; 21: 
281-3.
Kaur, G., Verhamme, K. M. C., Dieleman, J. P., Vanrolleghem, A., 8. 
Van Soest, E. M., Stricker, B. H. C.et al. Association between cal-
cium channel blockers and gingival hyperplasia. J Clin Periodon-
tol. 2010; 37: 625–30.
Nyska A,  Shemesh M , Tal H,  Dayan D. Gingival hyperplasia 9. 
induced by calcium channel blockers: mode of action.  Med Hypo-
theses. 1994; 43: 115-8.
Das SJ, Olsen I. Keratinocyte growth factor is upregulated by hy-10. 
perplasia-inducing drug nifedipine. Cytokine. 2000; 12:1566-9.
Trackman P.C., Kantarci A. Connective tissue metabolism and gin-11. 
gival overgrowth. Crit Rev Oral Biol Med. 2004; 15: 165-75.
Seymour RA. Effects of medications on the periodontal tissues in 12. 
health and disease. Periodontol 2000. 2006; 40: 120-9.
Westbrook P, Bednarczyk EM, Carlson M, Sheehan H, Bissada NF. 13. 
Regression of nifedepine Induced gingival hyperplasia following 
switch to a same class calcium channel blocker, Isradipine. J Perio-
dontol. 1997; 68: 645-50.
Camargo PM, Melnick PR, Pirih  F R Q, Lagos R,  Takei H.H. 14. 
Treatment of drug-induced gingival enlargement: aesthetic and 
functional considerations. Periodontol 2000. 2001; 27: 131–8.
Jorgensen MG. Prevalence of Amlodipine-related gingival hyper-15. 
plasia. J Periodontol. 1997; 68: 676-8.
